Figure 1

SOX6 blocks leukemia development. (a) Growth kinetics of B-ALL cells transduced either with viral particles carrying the SOX6-IRES-ΔNGFR (SOX6) or with EV-IRES-ΔNGFR (EV) vectors. (b) Analysis of spleens from mice injected with 10⁶ B-ALL transduced cells. Spleens were collected, measured, weighted (histogram bars: mean ± SEM n = 9; *p value < 0.05; **p value < 0.01; ***p value < 0.001) and compared to spleens from PBS-injected control animals (CTRL). (c) The transduced B-ALL engraftment contribution was assessed by tracking GFP⁺ cells (B-ALL cells) and GFP⁺ ΔNGFR⁺ double positive cells (B-ALL cells transduced with either SOX6 or EV) by flow cytometry (histogram bars: mean ± SEM; n = 9; *p value < 0.05; **p value < 0.01; ***p value < 0.001 P). (d) The same analysis was performed on explanted bone marrow cells grown ex vivo for 9 days (D1–D9) (histogram bars: mean ± SEM; n = 3). (e) Transduced cell lines growth curves. Transduced cells were ≥95% in each experiment, Fig. S1 (Graph points: mean ± SEM; n ≥ 3 *p value < 0.05; **p value < 0.01; ***p value < 0.001).